Pilot study of combined treatment with continuous infusion of 5-fluorouracil, mitomycin C, and cisplatin (FMP) in patients with inoperable advanced gastric cancer

We investigated combined chemotherapy with 5-fluorouracil (600 mg/m2/day, day 1-5, c.i.v.), mitomycin-C (6 mg/m2, day 6), and cisplatin (60 mg/m2, day 7) for inoperable advanced gastric cancer, including those with poor performance status (PS). Overall response rates were 62.5% (20/32), 59.1% (12/22) for PS 0-2 and 70.0% (7/10) for PS 3-4. Median survival was 7.2 months, 8.7 for PS 0-2; and 6.3 for PS 3-4. There was no serious toxicity or any treatment-related death. This therapy is useful, even for poor PS.